GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Get Free Report)'s stock price shot up 0.7% during trading on Wednesday . The stock traded as high as $3.81 and last traded at $3.71. 694 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 10,456 shares. The stock had previously closed at $3.68.
GENFIT Stock Up 0.7%
The company's fifty day simple moving average is $4.12 and its 200 day simple moving average is $3.80. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.08.
Institutional Trading of GENFIT
A hedge fund recently bought a new stake in GENFIT stock. Millennium Management LLC purchased a new position in GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 166,375 shares of the company's stock, valued at approximately $611,000. Millennium Management LLC owned about 0.33% of GENFIT as of its most recent SEC filing. 2.24% of the stock is currently owned by institutional investors and hedge funds.
About GENFIT
(
Get Free Report)
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GENFIT, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GENFIT wasn't on the list.
While GENFIT currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
